By Fineline Cube 
Sino-US liver therapy developer AusperBio announced that the National Medical Products Administration (NMPA) has approved the initiation of Phase III clinical trials for the company’s core candidate drug AHB-137. This approval is for the treatment of chronic hepatitis B and represents a significant milestone in the drug’s development.
About AHB-137
AHB-137 is a non-conjugated antisense oligonucleotide (ASO) with the potential to become a cornerstone in the clinical cure of chronic hepatitis B. It is the first innovative drug from AusperBio’s self-developed Med-Oligo platform to enter clinical trials.
Clinical Trial Progress
Currently, AHB-137 is undergoing a global Phase I clinical trial and several Phase II clinical trials in China. The drug’s development is advancing steadily, with the initiation of Phase III trials marking a crucial step toward its potential market approval and commercialization.-Fineline Info & Tech